Logo image
Endovascular therapies for malignant gliomas: Challenges and the future
Journal article   Peer reviewed

Endovascular therapies for malignant gliomas: Challenges and the future

YouRong Sophie Su, Rohaid Ali, Abdullah H. Feroze, Gordon Li, Michael T. Lawton and Omar Choudhri
Journal of clinical neuroscience, Vol.26, pp.26-32
04/01/2016
PMID: 26857294

Abstract

Anaplastic glioma Blood-brain barrier Endovascular GBM Glioblastoma Malignant gliomas
•Multiple approaches to endovascular therapy for gliomas have been developed.•These approaches have not all been successful.•However, endovascular disruption of the blood brain barrier shows great promise. Malignant gliomas are very difficult tumors to treat, with few effective therapies, early progression and high rates of recurrence. Here we review the literature on malignant gliomas treated with endovascular therapy. Endovascular therapy for malignant gliomas falls into one of three categories: (1) neoadjuvant embolization and devascularization; (2) direct intra-arterial drug delivery; and (3) disruption of the blood–brain barrier for improved intra-arterial drug delivery. There is a range of therapeutic benefits based on the endovascular intervention used. Challenges remain for those who aim to treat malignant gliomas with an endovascular approach. Specifically, embolization is difficult to accomplish in the small vessels that feed into malignant gliomas, and intra-arterial chemotherapy has yet to prove itself better than traditional intravenous chemotherapy. However, there exists promise in the therapeutic potential of intra-arterial chemotherapy paired with disruption of the blood–brain barrier at tumor-specific sites, and as such, continued research to optimize this approach is expected to yield benefit for patients with malignant gliomas.

Metrics

1 Record Views

Details

Logo image